Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders
The primary objectives of this study were to evaluate the efficacy of OROS-MPH (Concerta), relative to placebo, in treating ADHD and decreasing substance use in adolescents with ADHD and a substance use disorder. The study involved 303 participants, recruited from 11 community treatment sites.
Riggs, P., et al. (2011). Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. Journal of the American Academy of Child & Adolescent Psychiatry 50(9):903-14.
Participating Nodes and Community Treatment Programs
Ohio Valley Node (Lead Node)
Long Island Regional Node (Inactive)
Northern New England Node (Inactive)
As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.
Formed with SAMHSA to reduce the gap between research results and treatment.